A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
Phase: Phase I-II clinical trials
Principal Investigator: Dott. Pietrantonio Filippo
Main Facility: Oncologia Medica Gastroenterologica
Drug: MK-2870 (SKB264; sacituzumab tirumotecan; sac-TMT)
Pathologies: Bile duct cancer
ClinicalTrials.gov: Read the details about clinical trials
This is a Phase 1/2, nonrandomized, multisite, open-label study of MK-2870 monotherapy or in combination with other anticancer agents in GI cancers. Approximately 180 eligible participants will be nonrandomly allocated to one of the following disease cohorts:
• Cohort 3: 2L+ BTC (approximately 80 participants [approximately 40 participants each at 4 mg/kg and 5 mg/kg MK-2870])
• Cohort 4: 1L BTC (approximately 50 participants, including dose escalation)
The primary objectives of the study are to evaluate DLTs (Cohort 4, DoseEscalation Phase only), AEs, and discontinuation of study intervention due to AEs, and to evaluate ORR per RECIST 1.1 as assessed by BICR.
For Cohort 4, the totality of data, including safety and tolerability will be evaluated to determine the preliminary RP2D for MK-2870 in combination with cisplatin and pembrolizumab in Cohort 4 before opening enrollment in the Efficacy Phase of either cohort.
Last update: 16/07/2026